Biomedicinos technologijos - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 63,850 | 42,583 | 29,657 | 134,969 | 165,500 | 77,479 | 72,760 | 86,326 |
| Profit before tax | 49,398 | 31,483 | 21,822 | 114,631 | 66,571 | 61,385 | 25,937 | 53,856 |
| Net profit | 46,941 | 29,973 | 20,781 | 108,999 | 63,331 | 58,243 | 24,560 | 50,448 |
| Equity | 64,866 | 47,780 | 38,561 | 122,560 | 85,891 | 81,134 | 45,694 | 59,142 |
| Liabilities | 10,357 | 34,239 | 32,797 | 34,181 | 54,207 | 5,621 | 4,892 | 9,456 |
| Non-current assets | 2,885 | 4,295 | 4,951 | 6,111 | 17,782 | 13,171 | 8,634 | 4,899 |
| Current assets | 72,338 | 77,724 | 65,300 | 150,630 | 122,316 | 73,584 | 41,952 | 63,699 |
| Total assets | 75,223 | 82,019 | 70,251 | 156,741 | 140,098 | 86,755 | 50,586 | 68,598 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 35,047 | 27,364 | 23,641 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -2.6% | -33.3% | -30.4% | +355.1% | +22.6% | -53.2% | -6.1% | +18.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 62.4% | 36.5% | 29.6% | 69.5% | 45.2% | 67.1% | 48.6% | 73.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 72.4% | 62.7% | 53.9% | 88.9% | 73.7% | 71.8% | 53.7% | 85.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 73.5% | 70.4% | 70.1% | 80.8% | 38.3% | 75.2% | 33.8% | 58.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 77.4% | 73.9% | 73.6% | 84.9% | 40.2% | 79.2% | 35.6% | 62.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 0.7 | 0.9 | 0.3 | 0.6 | 0.1 | 0.1 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 36,486 | 36,499 | 29,657 | 134,969 | 165,500 | 77,479 | 62,364 | 45,039 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biomedicinos technologijos - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-11-16 | 2023-12-06 | 0.10 |
| 2023-10-25 | 2023-11-13 | 0.10 |
| 2023-09-18 | 2023-09-19 | 68.06 |
Biomedicinos technologijos - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biomedicinos technologijos, UAB (code 304039886) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In 2025, the company generated revenue of €86.3K and net profit of €50.4K, with a profit margin of 58.4%. Revenue increased by 18.6% year on year, while the two-year change was +11.4%, showing a recovery from the weaker 2024 result. The revenue trajectory moved from €77.5K in 2023 to €72.8K in 2024 and then to €86.3K in 2025. Net profit followed a similar pattern, declining from €58.2K in 2023 to €24.6K in 2024 before improving to €50.4K in 2025. At the end of 2025, total assets were €68.6K, equity €59.1K and liabilities €9.5K. The equity ratio was 86.2% and debt-to-equity stood at 0.16. Return on equity was 85.3% and return on assets 73.5%. Asset turnover was 1.26x. Revenue per employee was €86.3K and profit per employee €50.4K.